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Background.– TOWER is a prospective, Phase IV, dose titration clinical trial
(NCT01603459) investigating the safety and efficacy of incobotulinumtoxinA
(Xeomin®) in patients with spasticity, deemed to require doses higher than
currently approved.
Methods.– Patients (18–80 years) with upper- and lower-limb spasticity of
the same body side due to cerebral causes, deemed by the investigator to
require total body doses up to 800 U of incobotulinumtoxinA per injection
cycle, will undergo 3 injection cycles (400, 600, and 800 U incobotulinum-
toxinA, respectively), each followed by 12- to 16-week observation periods
with telephone contacts at 1 and 2 weeks and follow-up visits at 4, 8, and
12-16 weeks post-treatment. Co-primary outcome measures are adverse events
and investigator’s global assessment of tolerability. Muscle tone (Ashworth
Scale), Resistance to Passive Movement Scale, Functional Ambulation Clas-
sification scale, Goal Attainment Scale, Disability Assessment Scale, quality
of life, antibody formation, and pulmonary function will also be asses-
sed.
Results.– As of October 2013, patients (enrolment target 150) are being recruited
at 33 sites throughout Europe, Canada and the USA.
Conclusions.– TOWER will provide important insights into the safety and
efficacy of higher than currently recommended incobotulinumtoxinA doses in
patients with multifocal upper- and lower-limb spasticity.
http://dx.doi.org/10.1016/j.rehab.2014.03.174
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Background.– Studies have demonstrated reduction of spastic dystonia with
sustained stretch. The aim of the present work was to evaluate the effects
of upper limb wrist-worn loading in a patient with elbow flexor spastic
dystonia.
Methods.– A 53-year old male with left spastic hemiparesis secondary to a
cerebral infarct 2 years prior has benefited from a 3-month rehabilitation pro-
gram, including botulinum toxin injections at the Neurorehabilitation Day
Hospital in Albert-Chenevier hospital, Créteil, France. Within this program
the patient has worn a loaded wrist splint (1.5 kg) daily. Every day, he repor-
ted the total loading time together with any untoward effects in a diary.
Once monthly we monitored spasticity with the Tardieu Scale and active
arm function with the Modified Frenchay Scale using blinded review by two
examiners.
Results.– Maximal range of passive motion against the elbow flexors (XV1)
increased from 144◦ to 164◦ (+20◦), angle of catch (XV3) from 92◦ to 116◦
(+24◦) and active motion range (A) from 78◦ to 92◦ (+14◦). Regarding active
limb function, score improved by 1/10 point for three tasks involving active
elbow extension.
Conclusion.– Upper limb loading may be of benefit in hemiparesis to reduce
elbow flexor spastic dystonia and improve functionality.
http://dx.doi.org/10.1016/j.rehab.2014.03.175
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Background.– Type A botulinum toxin has been used in paraspinal muscles
for several conditions like stiff-person syndrome, back pain in cerebral palsy,
chronic low back pain, X-linked dystonia-parkinsonism.
Methods.– A 30-years old woman developed a spastic quadriplegia with right
side more involved, after a severe stroke at the age of 19. Although she was
following a rehabilitation programme for several years, she only improved her
ability to walk slowly for up to 30 steps unaided.
Results.– After treatment with type A botulinum toxin (Botox) for 6 years in limb
muscles, during the last 2 years, she developed a scoliosis which interfered with
her gait pattern. Right paraspinal thoracic muscles were injected, with botulinum
toxin in 6 segments, using 20 U in each site. This treatment was repeated 4 times
each year. Patient improved posture in standing position and facilitated the gait
pattern and velocity. She could walk more than 50 steps without assistance,
without body shifting and with a faster gait speed.
Conclusions.– Administration of botulinum toxin A reduced the tone of para-
spinal and improves significantly improvement of gait pattern in quadriplegic
woman.
http://dx.doi.org/10.1016/j.rehab.2014.03.176
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Background.– Intrathecal baclofen has been used to treat lower limb spasticity
in hereditary spastic paraparesis. Botulinum toxin type A has also been used for
the same reason.
Methods.– We present three cases of women (aged 47, 58, and 59) with hereditary
spastic paraparesis treated in our PRM department.
Results.– Patients were under intramuscular antispastic treatment with 400 U of
type A botulinum toxin for two years period, in hip adductors, hamstrings and
triceps surae. After 4, 8, 12, 16, 20 and 24 months of botulinum toxin, Modi-
fied Ashworth Scale showed improvement of spasticity not enough to improve
the gait velocity, measured with 10 m walking test. Patients were referred to
Neurosurgical department where they were treated with permanent intrathecal
baclofen pump, after positive test of 50g baclofen intrathecally. MAS score
was also improved but with not significant improvement in gait pattern. Daily
living activities were improved.
Conclusions.– Both botulinum toxin and intrathecal baclofen can reduce spas-
ticity in hereditary spastic paraparesis. Walking ability of these persons is still a
big question depending on the degree of paralysis and the severity of the disease.
http://dx.doi.org/10.1016/j.rehab.2014.03.177
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Background.– Current prescribing information recommends botulinum toxin
(BoNT) treatment intervals for cervical dystonia (CD) ≥ 12 weeks (≥ 10 weeks
for incobotulinumtoxinA European labelling). However, many patients expe-
rience recurrence of symptoms before 12 weeks have elapsed.
Methods.– A cross-sectional survey of patients with CD collected data on BoNT
treatment intervals received and preferred intervals [1]. These were compared
with intervals from an incobotulinumtoxinA clinical study in CD where patients
were re-injected at flexible intervals ≥ 6 weeks based on patients’ requests and
investigator-confirmed clinical need for retreatment [2].
Results.– Most (78.4%) patients in the survey (n = 136) preferred treat-
ment intervals ≤ 12 weeks; 46.3% preferred intervals ≤ 10 weeks. However,
47.1% of survey patients received intervals ≤ 12 weeks; 4.4% received inter-
vals ≤ 10 weeks. In the clinical study, 821 incobotulinumtoxinA treatments were
given at intervals of 6–20 weeks; 44.9% of treatments were given at intervals.
Conclusions.– Many patients with CD would like individualised BoNT treatment
regimens. When flexible treatment intervals are permitted, many patients choose
shorter or longer intervals than the 12-week standard-of-care interval.
References
[1] Sethi, et al. J Med Econ 2012;15:419–23.
[2] Evidente et al. Manuscript in preparation.
http://dx.doi.org/10.1016/j.rehab.2014.03.178
P219-e
Complications of intrathecal baclofen pump:
A case report
J. Pires a,∗, A. Ferreira a, M. Agundez b, I. Campos a
a Centro de Medicina de Reabilitac¸ão da Região Centro, Rovisco Pais, Tocha
b Servic¸o de Medicina B, Centro Hospitalar e Universitário de Coimbra,
Hospital Geral, Coimbra
∗Corresponding author.
Keywords: Intrathecal baclofen infusion system; spasticity; intrathecal
baclofen pump complications; baclofen withdrawal.
Background.– Intrathecal baclofen (ITB) infusion has become a common treat-
ment for severe spasticity. Many complications of these drug delivery systems
have been reported, such as those related to improper dosing, mechanical failure
of the implanted pump or catheter, or postoperative wound issues.
Results.– A 47-year-old man, with spastic paraplegia due to D4 ASIA A spinal
cord injury and right upper brachial plexus lesion, with a double barrel colostomy
to heal a perineal pressure sore, presented an abdominal wound dehiscence with
partial exposure of the ITB pump (350g/day, continuous), associated with signs
and symptoms of acute baclofen withdrawal, and eventual sepsis. As a result,
the patient underwent removal of the baclofen infusion system, closure with
plastic skin surgery, and placement of a new ITB infusion system (Synchromed
II, Medtronic), with the pump placed in the right abdominal region.
Conclusions.– Patients with baclofen pumps require periodic monitoring, not
only by the need to fill the pump, but also to assess the risk of complications
related to dosing or mechanical implant dysfunction, which can be serious
and life-threatening. It is important to inform patients about possible risks and
complications of this device in order to be aware of warning symptoms.
http://dx.doi.org/10.1016/j.rehab.2014.03.179
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Background.– We evaluated whether patients with longstanding upper extremity
(UE) post-stroke spasticity gain functional improvements through task-oriented
rehabilitation therapy combined with Xeomin (incobotulinumtoxinA) injec-
tions.
Methods.– Eleven consecutive patients (aged 37–80 years) with UE spasti-
city ≥ 2 years post-stroke (mean, 6.2 years; range, 2–24 years) and a Modified
Ashworth Scale (MAS) score > 3 for two joints received conventional rehabili-
tation therapy combined with Xeomin (three treatments per year administered
by the same physician using electromyographic guidance). Xeomin dose (target
range 130–400 U) and injected muscles depended on UE muscles involved. Out-
come measures included Disability Assessment Scale (DAS), muscle tone (using
MAS) and range of motion (ROM), assessed before and 1, 6 and 12 months after
the first Xeomin treatment.
Results.– After one year of rehabilitation therapy and Xeomin treatments, mean
DAS score improved from 1.6 to 0.9, mean MAS score decreased from 3.3 to 1.8
and mean ROM score increased from –22.5 to –7.7 (P < 0.0001 for all; ANOVA).
No adverse events occurred.
Conclusions.– In patients with longstanding UE post-stroke spasticity, Xeomin
combined with conventional rehabilitation therapy improved disability, muscle
tone and ROM and was well tolerated. Activities of daily living were improved
after the paralytic effects of Xeomin had largely diminished.
http://dx.doi.org/10.1016/j.rehab.2014.03.180
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Background.– Sonoelastography (SE), which is an ultrasound-based technique,
can assess tissue elasticity. The objective of the study is to assess forearm muscles
spasticity in patients with stroke.
Methods.– Twenty-three stroke patients (17 males %73,9; 6 females %26,1) who
had spasticity in forearm muscles (pronator teres, flexor carpi radialis, flexor
carpi ulnaris, flexor digitorum superficialis, flexor carpi ulnaris) were evaluated
with ultrasonography. Elasticity Index (E), which indicates the tissue elasticity,
was measured using SE. E value ranged from 0 to 6 (6 indicates hardest tissue).
The bulkiest part of the muscles in short axis was targeted for the measurement.
SE findings in affected side were compared with unaffected side.
Results.– E values and E ratio were higher in affected forearm muscles compared
to unaffected forearm muscles (P < 0.05).
Conclusions.– The results of the study suggested that SE could be used to assess
spasticity in forearm muscles.
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